



## **LB Pharmaceuticals, Inc. Announces Issuance of U.S. Patent Covering N-Methyl Amisulpride for the Treatment of Psychiatric Disorders**

*Issuance of U.S. Patent No. 10,167,256 is First in LB's IP Portfolio*

**New York, NY (January 1<sup>st</sup>, 2019)** – LB Pharmaceuticals, Inc., (“LB”, or the “Company”) a biotechnology company focused on developing and commercializing novel and improved versions of successful CNS treatments, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10.167.256 which covers *N*-Methyl Amisulpride for the treatment of various forms of psychiatric disorders.

The Company’s first issued U.S. patent claims the composition of matter of various derivatives of *N*-methyl amisulpride, and uses thereof for inhibiting dopamine and/or 5-HT<sub>2a</sub> and/or  $\alpha$ <sub>2</sub> receptors to treat a disorder or condition selected from the group consisting of depression, bipolar disorder, Tourette’s syndrome, Schizoaffective disorder, Parkinson’s psychosis, Alzheimer’s psychosis, oppositional defiant disorder, personality disorder, childhood schizophrenia, dysthymia, treatment resistant schizophrenia, and chronic fatigue syndrome until the statutory term expires November 28, 2037 (not including any patent term extension under the Hatch-Waxman Act).

“We are pleased to announce the issuance of our first U.S. patent,” said Zachary Prensky, President and CEO of LB. “This milestone validates our approach of developing novel, improved versions of existing anti-psychotic treatments. If approved, LB-102 would be the first benzamide product available to treat U.S. patients suffering from schizophrenia and thus may improve the quality of care of thousands of patients currently not responding to existing treatments.”

### **About LB Pharmaceuticals**

LB is a development stage CNS-focused life science company devoted to commercializing novel and improved versions of successful CNS treatments used extensively overseas but never developed, approved, or marketed, in the United States. Our approach is to create a research-focused organization dedicated to generating novel intellectual property around improved versions of these former best-selling drugs. We have a low-risk, high-reward drug development business plan: Invest in bringing to the US market patented, branded, first-to-market versions of standard-of-care CNS therapies currently in use worldwide

### **Contact**

Zachary Prensky, President & CEO

[Zach@LBPharma.us](mailto:Zach@LBPharma.us) (212) 605-0230

575 Madison Avenue, 10<sup>th</sup> Floor NY NY 10022